{{Rsnum
|rsid=7997012
|Gene=HTR2A
|Chromosome=13
|position=46837850
|Orientation=plus
|GMAF=0.2741
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=HTR2A
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 9.7 | 51.6 | 38.7
| HCB | 13.3 | 28.9 | 57.8
| JPT | 0.0 | 31.8 | 68.2
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 13.3 | 28.9 | 57.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
[[rs7997012]], located in an intron of the [[HTR2A]] gene, was found to be associated with a somewhat increased rate of successful response to treatment of [[depression]] with the drug [[citalopram]]. {{PMID|16642436|OA=1
}}

From this article {{PMID|16642436|OA=1
}}:

"[[HTR2A]] encodes the serotonin 2A receptor, which is downregulated by [[citalopram]]. Participants who were homozygous for the A allele had an 18% reduction in absolute risk of having no response to treatment, compared with those homozygous for the other allele."

* See also [http://www.anxietyinsights.info/antipressant_effectiveness_predicted_by_gene_variation.htm Anxiety Blog] posting

{{PMID Auto
|PMID=19095219
|Title=Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder
}}

{{omim
|id=182135
|desc=5-@HYDROXYTRYPTAMINE RECEPTOR 2A; HTR2A
|rsnum=7997012
}}
{{PMID Auto
|PMID=19428704
|Title=Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population
}}
{{PMID Auto
|PMID=19590397
|Title=5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression
}}
{{PMID Auto
|PMID=19924111
|Title=Polymorphisms in GRIK4, HTR2A, and FKBP5 Show Interactive Effects in Predicting Remission to Antidepressant Treatment
|OA=1
}}

{{PharmGKB
|RSID=rs7997012
|Name_s=5-HTR2A intron 2 variant
|Gene_s=HTR2A
|Feature=
|Evidence=PubMed ID:19636338
|Annotation=Risk or phenotype-associated allele: A. Phenotype: Patients with the 5-HTR2A intron 2 (rs7997012) AA genotype suffered from more pronounced side effects compared to carriers of the GA or GG genotype. Study size: 124. Study population/ethnicity: Caucasian; Patients with psychiatric disorders. Significance metric(s): p = 0.018 and p = 0.002. Type of association: PD.
|Drugs=olanzapine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165109601
}}

{{PMID Auto
|PMID=19758789
|Title=HTR2A gene variation is involved in antidepressant treatment response
}}

{{PharmGKB
|RSID=rs7997012
|Name_s=
|Gene_s=HTR2A
|Feature=
|Evidence=PubMed ID:16642436
|Annotation=In one study, subjects homozygous for allele A had a reduction in absolute risk of having no response to treatment with citalopram for major depressive disorder. The allele was found to be more frequent in white than in black subjects, and this is consistant with racial differences in response to antidepressant treatment.
|Drugs=citalopram
|Drug Classes=
|Diseases=Depressive Disorder, Major
|Curation Level=Curated
|PharmGKB Accession ID=PA161614203
}}

{{omim
|id=182135
|rsnum=7997012
|variant=0003
}}

{{PMID Auto
|PMID=22006095
|Title=Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder
}}

{{PMID Auto
|PMID=18803430
|Title=Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.
|OA=1
}}

{{PMID Auto
|PMID=19077664
|Title=Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response.
|OA=1
}}

{{PMID Auto
|PMID=19381154
|Title=Differences and similarities in the serotonergic diathesis for suicide attempts and mood disorders: a 22-year longitudinal gene-environment study.
}}

{{PMID Auto
|PMID=19937159
|Title=HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.
}}

{{PMID Auto
|PMID=20047709
|Title=Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB.
|OA=1
}}

{{PMID Auto
|PMID=20194481
|Title=Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder.
|OA=1
}}

{{PMID Auto
|PMID=20453658
|Title=5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.
}}

{{PMID Auto
|PMID=21136126
|Title=Temperament profiles, 5-HT2A genotype, and response to treatment with SSRIs in major depression.
}}

{{PMID Auto
|PMID=21172166
|Title=Pharmacogenetics of antidepressant response.
|OA=1
}}

{{PMID Auto
|PMID=21741447
|Title=Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7997012
|overall_frequency_n=98
|overall_frequency_d=128
|overall_frequency=0.765625
|n_genomes=52
|n_genomes_annotated=0
|n_haplomes=91
|n_articles=2
|n_articles_annotated=2
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23798967
|Title=No Effect of Serotoninergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression
|OA=1
}}

{{PMID Auto
|PMID=22907732
|Title=Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.
}}

{{PMID Auto
|PMID=23733030
|Title=Pharmacogenetics in major depression: a comprehensive meta-analysis.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}